Clinical trial NCT02891460: Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
Official title: Evaluation of the Clinical Response of Mitomycin-C (MMC) Embedded in Hydrogel (TC-3) in Comparison to Mitomycin C in Saline, When Administered Intravesically, Pre-TURBT in Non Muscle Invasive Bladder Cancer (NMIBC) Patients. Muscle Invasive Bladder Cancer (NMIBC) Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Urinary Bladder Neoplasms
Urologic Neoplasms
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Keywords: Mitomycin C
MMC
NMIBC
Non Muscle Invasive Bladder Cancer
Hydrogel Reverse thermal gelation
Drug retention
Urinary Bladder Neoplasms
Urologic Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Lead sponsor: UroGen Pharma Ltd.
Sponsor class: INDUSTRY
First posted: 2016-09-07
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the clinical response of the tumors within the bladder of recurrent NMIBC patients to Mitomycin-C embedded in UroGen Pharma's (known at that time as TheraCoat Ltd.) TC-3 Sterile Hydrogel (TC-3) and to evaluate the patency of ureters 6 hr post instillation.

Detailed description: An open label, successive dose escalation trial in subjects with Non Muscle Invasive Bladder Cancer (NMIBC), designed to evaluate the clinical response of low-intermediate risk tumors within the bladder to Mitomycin-C embedded in TC-3 Sterile Hydrogel (TC-3), administered intravesically, prior to TURBT in NMIBC subjects.

Eligible subjects with NMIBC will be recruited to the trial following the initial diagnostic cystoscopy. During the diagnostic cystoscopy, the number of tumor lesions, their size and location will be documented and recorded with video or photo cystoscopy.

A baseline cystoscopy will be conducted in all subjects for the evaluation of number of tumors and their diameters, and for mapping of their location. Baseline blood samples for liver and renal functions, as well as for complete blood count (CBC) and coagulation tests will be drawn prior to instillation to ensure eligibility and to serve as a reference point for systemic safety follow-up.

A future TURBT has been planned for 8-10 weeks post screening. Enrolled subjects will be treated successively with 40mg MMC in 40 mL TC-3 (the first 6 subjects) and with 80 mg MMC in 40 mL TC-3 (the following 12 subjects). At treatment session initiation, an 18-20 Fr two-way catheter will be inserted into the subject's bladder in order to completely empty the bladder of urine. Thereafter, a volume of 40 mL of cooled TC-3 mixed with 40 mg or 80 mg of MMC will be instilled through the catheter into the bladder of the subject. The catheter will then be ligated for twenty minutes, after which it will be drawn out of the bladder and the subject was will be allowed to urinate freely.

The subjects will undergo six weekly bladder instillations according to their assigned treatment of either 40 mg MMC (Group A) or 80 mg MMC (Group B) in 40 mL of TC-3. Following completion of instillation treatment series, there will be a 2-4 weeks healing period prior to next follow up visit (overall 10-12 weeks post screening). During 2-4 weeks follow-up (FU) visit, the lesions' status will be examined under cystoscopy. For subjects who will appear to have complete response (CR), this will be confirmed based on histological results. For subjects that will not be classified as having CR, decision about performance of TURBT or giving additional treatment will be at the PI's discretion.

Following 2-4 week FU visit, subjects will be managed according to their local standard guidelines. All patients will attempt to be followed up for 12 months following 2-4 weeks FU within the trial. These visits will be documented and data regarding recurrence and progression will be collected. Moreover, biopsy slides prior (when available), and following treatment will be collected and analyzed by an independent uro-pathologist.

Eligibility criteria: Main Inclusion criteria:

1. Single or multiple tumors (n≤7)
2. Recurrent or Naive tumor.
3. No prior history of T1 and/or Tis
4. At least one tumor \>1mm.
5. Largest tumor diameter ≤ 30mm
6. Cystoscopic appearance of papillary Low or high grade tumor

Main Exclusion Criteria:

1. Carcinoma In Situ (CIS)
2. Over 7 lesions
3. Lesion is larger than 30mm in diameter
4. Cystoscopic appearance suspicious for Tis
5. Tumor located in prostatic urethra
6. Previous systemic chemotherapy or pelvic radiotherapy.

Primary outcomes:
measure: Subject's degree of response at 2-4 weeks post-treatment
timeFrame: 9-11 weeks
measure: Adverse events (AE) including serious adverse events (SAE)
timeFrame: 1.2 years
measure: Anesthesia information
timeFrame: 7 weeks
measure: Blood and urine tests
timeFrame: 9-11 weeks
measure: The degree of pain during treatment
timeFrame: 7 weeks
measure: Gel clearance and urinary patency
timeFrame: 7 weeks
Secondary outcomes:
measure: Tumor recurrence rate during 12 months post- 2-4 week follow-up visit in complete response (CR) subjects.
timeFrame: 1.2 years
measure: Lesion Mass by time point (Screening and 2-4 weeks post-treatment)
timeFrame: 9-11 weeks
Other outcomes:
measure: Subjects' satisfaction with the treatment
timeFrame: 9-11 weeks
Locations:
city: Delhi
country: India
facility: Rajiv Gandhi Cancer Institute & Research Center
state: New Delhi
Study officials:
affiliation: Rajiv Gandhi Cancer Institute & Research Center
name: Sudhir Rawal, MD
role: PRINCIPAL_INVESTIGATOR
References: